Sandoz

Novartis | July 10, 2017

Today's approval of Rixathon represents a big win for patients in Europe with blood cancers or immunological diseases because it enables increased access to biologics. It also allows healthcare systems to redeploy resources to other areas of high need, particularly innovative therapies said Carol Lynch, Global Head, Biopharmaceuticals, Sandoz. Sandoz is committed to increasing patient access to biologic medicines, and Rixathon will be one of the five major launches we plan in the next four years...

Novartis | January 18, 2018

Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangemen...

fiercepharma | May 25, 2018

Novartis has been looking to jettison some assets in its North American generics business, but as it turns out, it is a manufacturing facility in Canada that will be sold off first. Avara Pharmaceutical Services has inked a deal to buy Novartis Technical Operations’ sterile manufacturing facility and the nearby Sandoz Development Center on Sandoz’s Canada campus in Boucherville, Quebec. The site is the biggest injectables production facility in Canada and provides drugs to the Canadi...

Pharmaphorum Media Limited | October 05, 2018

Sandoz has announced a second competition inviting entrepreneurs and innovators in digital health to submit ideas that could complement or even disrupt established approaches to access to healthcare. The competition, known as the Sandoz Healthcare Access-Challenge (HACk) opened this week and entries close on November 30. Novartis’ generics and biosimilars division said universal access to health is still the largest unmet medical need. Despite some success, access varies hugely across geog...